Kabra Drugs P/E Ratio
Current P/E Ratio
6.29
Low Valuation
Very Low - Potentially undervalued or facing challenges
Kabra Drugs (KABRADG) P/E ratio is 6.29 (Low), EPS (TTM) ₹2.09, current price ₹19.08 on BSE — Very Low - Potentially undervalued or facing challenges. Also explore KABRADG share price data to track price trends across different timeframes.
Current Valuation Metrics
P/E Ratio
6.29
Current Price
₹19.08
EPS (TTM)
₹2.09
Exchange
BSE
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
56.99
Sector Median
32.06
Sector Rank
#10 of 199
Sector Percentile
5.0%
KABRADG P/E Ratio — Valuation Signal & Historical Context
Kabra Drugs P/E 6.29 — signal: Undervalued.
- Stock appears undervalued with PE of 6.29, suggesting potential buying opportunity
- Trading at discount to sector average PE of 56.99
KABRADG vs Healthcare Peers — P/E Ratio Comparison
Kabra Drugs P/E 6.29 vs Healthcare average 56.99, median 32.06 — range 1.99–747.21.
Sector Average
56.99
Sector Median
32.06
Lowest P/E
1.99
Highest P/E
747.21
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Royal Sense | ROYAL | 7.11 | ₹50 | Low |